Synergistic mechanism of olaparib and cisplatin on breast cancer elucidated by network pharmacology
Abstract Cisplatin is an important chemotherapeutic agent is widely used to treat breast cancer and olaparib is the most studied PARP inhibitor to date. To explore the combinational anti-cancer potential and synergistic mechanism of Olaparib and cisplatin in breast cancer using network pharmacology....
Saved in:
| Main Authors: | Qiang Niu, Tao Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-99741-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification and Characterization of Novel Inhibitors of Human Poly(ADP-Ribose) Polymerase-1
by: Ibrahim Morgan, et al.
Published: (2025-06-01) -
β-Sitosterol Synergizes Cisplatin's Anti-Lung Cancer Activity: A Cell Line Study
by: Wisam Selman, et al.
Published: (2025-06-01) -
Combination of Cannabidiol with Cisplatin or Paclitaxel Analysis Using the Chou–Talalay Method and Chemo-Sensitization Evaluation in Platinum-Resistant Ovarian Cancer Cells
by: Jana Ismail, et al.
Published: (2025-02-01) -
Bioinformatics-based identification of key genes for Olaparib resistance in breast cancer: prognostic implications and therapeutic relevance
by: Kezhen Shen, et al.
Published: (2025-06-01) -
Synergistic ideas in oncology: prospects for practical implementation
by: E. S. Evstratova, et al.
Published: (2020-06-01)